result 47822 件
| Author | Nasu, Yasutomo| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| Author | Kobashi, Kenta| Ishii, Hiroshi| Nishiyama, Kanako| Matsumi, Yuki| Hatano, Masahide| Fujiwara, Masamitsu| Kurokawa, Tatsuo| Tsunemitsu, Kensuke| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| Author | Gotoda, Tatsuhiro| Kawano, Seiji| Kono, Yoshiyasu| Miura, Kou| Kanzaki, Hiromitsu| Iwamuro, Masaya| Kawahara, Yoshiro| Tanaka, Takehiro| Yoshino, Tadashi| Shirakawad, Yasuhiro| Tabata, Masahiro| Tanimoto, Mitsune| Okada, Hiroyuki| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| Author | Iwamuro, Masaya| Okada, Hiroyuki| Harada, Keita| Kanzaki, Hiromitsu| Hori, Keisuke| Kita, Masahide| Kawano, Seiji| Kawahara, Yoshiro| Tanaka, Takehiro| Yamamoto, Kazuhide| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| Author | Kunisue, Mitsuhisa| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| Author | Mizukawa, Nobuyoshi| Onoda, Tomoo| Matsumoto, Hiroshi| Takeda, Seiko| Noda, Youhei| Onoda, Satoshi| Fukushima, Mai| Tsumura, Munechika| Takeuchi, Tetsuo| Sugiyama, Narushi| Kimata, Yoshihiro| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| Author | Kobayashi, Katsuhiro| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| Author | Shigeyasu, Kunitoshi| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| Author | Mizoue, Ryoichi| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| Author | Nosaka, Nobuyuki| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| Author | Fujiwara, Hideaki| |
|---|---|
| Published Date | 2016-12-01 |
| Publication Title | Journal of Okayama Medical Association |
| Volume | volume128 |
| Issue | issue3 |
| Content Type | Journal Article |
| JaLCDOI | 10.18926/AMO/54608 |
|---|---|
| FullText URL | 70_5_429.pdf |
| Author | Asano, Takeru| Matsuoka, Ken-ichi| Iyama, Satoshi| Ohashi, Kazuteru| Inamoto, Yoshihiro| Ohwada, Chikako| Murata, Makoto| Satake, Atsushi| Yoshida, Chikamasa| Nakase, Koichi| Mori, Yasuo| Tanimoto, Mitsune| |
| Abstract | Chronic graft versus host disease (cGVHD) remains a major problem for long survivors after allogeneic hematopoietic stem cell transplantation (HSCT). Currently, corticosteroid therapy is effective for cGVHD as the first line therapy. However, prolonged therapy with corticosteroids causes various severe adverse events. To develop the new therapeutic strategy of cGVHD, we have launched a multicenter phase I/IIa clinical trial of low dose subcutaneous interleukin-2 (IL-2) for treatment of steroid refractory cGVHD, which is constituted of 2 sequential phases (induction phase and maitanance phase). This study will provide the new therapeutic option for patients with refractory cGVHD after allogeneic HSCT. |
| Keywords | chronic GVHD allogeneic HSCT steroid refractory IL-2 |
| Amo Type | Clinical Study Protocols |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-10 |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 429 |
| End Page | 433 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777442 |
| Web of Science KeyUT | 000388098700019 |
| JaLCDOI | 10.18926/AMO/54607 |
|---|---|
| FullText URL | 70_5_425.pdf |
| Author | Tamura, Tomoki| Hirata, Taizo| Tabata, Masahiro| Hinotsu, Shiro| Hamada, Akinobu| Motoki, Takayuki| Iwamoto, Takayuki| Mizoo, Taeko| Nogami, Tomohiro| Shien, Tadahiko| Taira, Naruto| Matsuoka, Junji| Doihara, Hiroyoshi| |
| Abstract | Docetaxel is a standard treatment for patients with advanced or recurrent breast cancer. The recommended dose is 60 to 100 mg/m2. Previous study have shown that the tumor response rates of patients who received docetaxel monotherapy at doses of 60, 75, and 100 mg/m2 were 22.1% , 23.3% , and 36.0% , respectively, and there was a significant relationship between the dose and response. In Europe and the United States, docetaxel is approved at a dose of 100 mg/m2, and Japanese guidelines also recommend a dose of 100 mg/m2. However, the approved dose in Japan is up to 75 mg/m2. We have launched a phase I trial evaluating 100 mg/m2 docetaxel in patients with advanced or relapsed breast cancer. The major eligibility criteria are as follows: age ≥20 years, pathologically diagnosed breast cancer, recurrent or advanced breast cancer, a good performance status, and HER2 [human epidermal growth factor receptor 2] negative. The primary endpoint is demonstrated safety of 100 mg/m2 docetaxel. This study will clarify whether 100mg/m2 docetaxel can be administrated safely in Japanese patients with advanced or recurrent breast cancer. |
| Keywords | breast cancer phase I trial docetaxel |
| Amo Type | Clinical Study Protocols |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-10 |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 425 |
| End Page | 427 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777441 |
| Web of Science KeyUT | 000388098700018 |
| JaLCDOI | 10.18926/AMO/54606 |
|---|---|
| FullText URL | 70_5_421.pdf |
| Author | Ohki, Takashi| Sugimoto, Seiichiro| Kurosaki, Takeshi| Otani, Shinji| Miyoshi, Kentaroh| Yamane, Masaomi| Miyoshi, Shinichiro| Oto, Takahiro| |
| Abstract | Stent placement is an essential treatment for airway diseases. Although self-expandable metallic stents and silicone stents are commonly applied for the treatment of airway diseases, these stents are unsuitable for the treatment of small airway diseases encountered in pediatric patients and lung transplant recipients with airway complications. Currently, only vascular balloon-expandable metallic stents are available for the treatment of small airway diseases; however, little research has been conducted on the use of these stents in this field. We have launched a prospective feasibility study to clarify the safety and efficacy of balloon-expandable metallic stents for the treatment of airway diseases. |
| Keywords | metallic stent airway disease lung transplantation airway complication airway malignancy |
| Amo Type | Clinical Study Protocols |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-10 |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 421 |
| End Page | 424 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777440 |
| Web of Science KeyUT | 000388098700017 |
| JaLCDOI | 10.18926/AMO/54605 |
|---|---|
| FullText URL | 70_5_417.pdf |
| Author | Mizukawa, Sho| Kato, Hironari| Muro, Shinichiro| Akimoto, Yutaka| Uchida, Daisuke| Tomoda, Takeshi| Matsumoto, Kazuyuki| Yamamoto, Naoki| Horiguchi, Shigeru| Tsutsumi, Koichiro| Okada, Hiroyuki| Inoue, Hirofumi| Tanaka, Noriyuki| |
| Abstract | Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is a standard procedure for precise histological diagnosis of pancreas tumors, but it is sometimes difficult to obtain adequate specimens. EUS Sonopsy CY® is a newly designed needle with original features. This randomized study will compare the tissue collection rate of EUS Sonopsy CY® to that of a conventional needle in EUS-FNA. The major eligibility criteria are as follows: Patients with a pancreatic mass referred for EUSFNA; age ≥20 years, and performance status＜4. The primary outcome is the tissue collection rate. This study will elucidate the efficacy of EUS Sonopsy CY®. |
| Keywords | endoscopic ultrasound-guided fine needle aspiration pancreatic cancer Menghini type needle tip |
| Amo Type | Clinical Study Protocols |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-10 |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 417 |
| End Page | 420 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777439 |
| Web of Science KeyUT | 000388098700016 |
| JaLCDOI | 10.18926/AMO/54604 |
|---|---|
| FullText URL | 70_5_413.pdf |
| Author | Murakami, Takashi| Kawanabe, Noriaki| Kataoka, Tomoki| Hoshijima, Mitsuhiro| Komori, Hiroki| Fujisawa, Atsuro| Kamioka, Hiroshi| |
| Abstract | Although accurate bracket placement is essential for orthodontic treatment, many practitioners apply brackets indiscriminately with direct or indirect bonding techniques. Nonetheless, there have been few prospective clinical comparisons of the 2 techniques. We will therefore conduct a single-center, randomized control trial in 100 patients aged ≥12 years and diagnosed with malocclusion. All patients will receive orthodontic treatment using brackets with direct or indirect bonding techniques. The primary endpoints will be the total treatment time, occlusal index, discomfort at bonding, and oral hygiene after bonding. This study will clarify whether indirect bonding can improve the efficiency of orthodontic treatment. |
| Keywords | indirect bonding comprehensive evaluation bracket |
| Amo Type | Clinical Study Protocols |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-10 |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 413 |
| End Page | 416 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777438 |
| Web of Science KeyUT | 000388098700015 |
| JaLCDOI | 10.18926/AMO/54603 |
|---|---|
| FullText URL | 70_5_409.pdf |
| Author | Maeda, Yoshinobu| Nishimori, Hisakazu| Inamoto, Yoshihiro| Nakamae, Hirohisa| Sawa, Masashi| Mori, Yasuo| Ohashi, Kazuteru| Fujiwara, Shin-ichiro| Tanimoto, Mitsune| |
| Abstract | Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity following allogeneic hematopoietic cell transplantation (HSCT). Retinoic acid (tamibarotene) exerts multiple effects on cell differentiation and is clinically used for the treatment of acute promyelocytic leukemia. Tamibarotene down-regulates both Th1 and Th17 differentiation in donor T cells after allogeneic HSCT, resulting in attenuation of experimental chronic GVHD. Based on preclinical data, we have launched a phase II study of tamibarotene in patients with steroid-refractory chronic GVHD. This study will clarify whether tamibarotene can exert beneficial effects in patients with steroid-refractory chronic GVHD. |
| Keywords | Am80 tamibarotene retinoid chronic GVHD steroid-refractory GVHD |
| Amo Type | Clinical Study Protocols |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-10 |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 409 |
| End Page | 412 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777437 |
| Web of Science KeyUT | 000388098700014 |
| JaLCDOI | 10.18926/AMO/54602 |
|---|---|
| FullText URL | 70_5_405.pdf |
| Author | Tomoda, Takeshi| Kato, Hironari| Mizukawa, Sho| Muro, Shinichiro| Akimoto, Yutaka| Uchida, Daisuke| Matsumoto, Kazuyuki| Yamamoto, Naoki| Horiguchi, Shigeru| Tsutsumi, Koichiro| Okada, Hiroyuki| |
| Abstract | Acute pancreatitis is the major complication of endoscopic retrograde cholangiopancreatography (ERCP). A preliminary research suggested that the administration of nonsteroidal anti-inflammatory drugs (NSAIDs) with nitroglycerin might reduce the incidence of post-ERCP pancreatitis (PEP) more effectively than NSAIDs alone. We conduct a two-arm, multicenter, prospective, randomized, superiority trial to evaluate the additional effect of nitroglycerin for prevention of PEP. A total of 900 patients randomly receive 50 mg diclofenac suppository either alone or with 5 mg isosorbide dinitrate sublingual tablet. The primary endpoint is the occurrence of PEP. This study will clarify whether NSAIDs plus nitroglycerin can prevent PEP. |
| Keywords | post-ERCP pancreatitis NSAIDs nitroglycerin |
| Amo Type | Clinical Study Protocols |
| Note | the word “nitroglycerin” should be corrected to “nitrate” throughout the manuscript.| |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-10 |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 405 |
| End Page | 408 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777436 |
| Web of Science KeyUT | 000388098700013 |
| Related Url | isReplacedBy http://doi.org/10.18926/AMO/55314 |
| JaLCDOI | 10.18926/AMO/54601 |
|---|---|
| FullText URL | 70_5_401.pdf |
| Author | Kuroda, Shinji| Kikuchi, Satoru| Nishizaki, Masahiko| Kagawa, Shunsuke| Hinotsu, Shiro| Fujiwara, Toshiyoshi| |
| Abstract | Although intermittent pneumatic compression (IPC) has become common as perioperative prophylaxis for venous thromboembolism (VTE) consisting of pulmonary thromboembolism (PE) and deep vein thrombosis (DVT), the prophylactic effect against VTE, especially lethal PE, is not yet satisfactory. Therefore, pharmacologic prophylaxis, such as with enoxaparin, is desirable. While the efficacy and safety of enoxaparin have been proven in several clinical trials, concern about bleeding with longterm (at least 7 days) use have potentially decreased its widespread adoption. We have launched a phase II study to evaluate the efficacy and safety of short-term (3 days) enoxaparin, in which a total of 70 gastric cancer patients undergoing gastrectomy will be recruited, and the primary endpoint is the incidence of DVT. This study could contribute to making pharmacologic prophylaxis for VTE more common. |
| Keywords | venous thromboembolism enoxaparin short-term use gastric cancer surgery |
| Amo Type | Clinical Study Protocols |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-10 |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 401 |
| End Page | 404 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777435 |
| Web of Science KeyUT | 000388098700012 |
| JaLCDOI | 10.18926/AMO/54600 |
|---|---|
| FullText URL | 70_5_397.pdf |
| Author | Akagi, Satoshi| Nakamura, Kazufumi| Akagi, Teiji| Nakagawa, Koji| Takaya, Yoichi| Sarashina, Toshihiro| Ejiri, Kentaro| Ito, Hiroshi| |
| Abstract | A treatment strategy for patients with pulmonary hypertension (PH) and atrial septal defect (ASD) remains unclear. This study was designed to evaluate the effects of initial repair of ASD followed by treatment with PH-specific drugs in patients with PH and ASD. Eligible patients receive transcatheter ASD closure followed by treatment with bosentan and sildenafil. Right heart catheterization is performed at baseline and at 12, 24 and 48 weeks. The primary endpoint is change in pulmonary artery pressure and pulmonary vascular resistance from baseline to follow-up. This study should provide valuable information to establish a therapeutic strategy for PH and ASD. |
| Keywords | pulmonary hypertension atrial septal defect repair and treat transcatheter closure |
| Amo Type | Clinical Study Protocols |
| Publication Title | Acta Medica Okayama |
| Published Date | 2016-10 |
| Volume | volume70 |
| Issue | issue5 |
| Publisher | Okayama University Medical School |
| Start Page | 397 |
| End Page | 400 |
| ISSN | 0386-300X |
| NCID | AA00508441 |
| Content Type | Journal Article |
| language | English |
| Copyright Holders | CopyrightⒸ 2016 by Okayama University Medical School |
| File Version | publisher |
| Refereed | True |
| PubMed ID | 27777434 |
| Web of Science KeyUT | 000388098700011 |
